Study for adults with acute myeloid leukemia (AML)
Part of Blood & lymphatic, Cancer clinical trials.
This non-interventional study follows adults with acute myeloid leukemia (AML) to better understand the disease and how patients do in real-world care. It may help researchers compare outcomes across different types of AML, but you would not receive a study treatment just for joining.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- You have a confirmed diagnosis of acute myeloid leukemia (AML)
- Your AML is one of these: newly diagnosed, or AML that came back (relapsed) or did not respond (refractory)
- You have health insurance
- Your body weight is at least 50 kg (about 110 lb)
- You are not against joining the study (you agree to participate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study enrolls adults with acute myeloid leukemia (AML) to build a detailed registry and store biological samples. It helps researchers understand AML better and may support future studies.
This study collects health information from young people with a type of blood cancer called acute myeloid leukemia (AML). The goal is to learn more about the disease and improve future treatments. If you are under 25 and being treated for AML at a hospital in France, you might be able to join.
This is a research registry that collects information and lab/blood sample data to better understand what acute leukemia looks like biologically and how patients do over time. It may help future treatment decisions, but it does not describe testing a new drug.
This study looks at how acute myeloid leukemia behaves over time in adults and may help doctors better predict outcomes. You might be eligible if you have AML and agree to take part in research.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study follows people aged 60 and older with newly diagnosed acute myeloid leukemia (AML) who are receiving strong chemotherapy. It aims to learn more about their health outcomes and better understand the disease in this age group.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.